Omnes Capital's investments

Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.

A SaaS developer, viavoo can provide real-time analysis of consumer feedback to gain insight into their online or point-of-sale shopping experience, their views about products and services or about after-sales service, etc.
Operating across multiple channels (email, chat, satisfaction surveys, blogs, forums, opinions, social media), the linguistic technology developed by viavoo provides results very close to human understanding and can identify situations, questions, opinions, suggestions, intentions and complaints in customer feedback.
The data collected by viavoo is intended to provide marketing and customer relationship insights that help to use the customer’s own voice to improve customer experience, differentiation, loyalty and retention.

Founded in 1999 and headquartered in Germany, the company audits online stores applying a set of over 100 criteria, such as solvency, price transparency, customer service and personal data protection. After a successful audit, Trusted Shops issues the Trust Badge seal of approval and provides the option of a guarantee for shoppers. Today, more than 20,000 ecommerce sites across Europe display the seal of approval and over 10 million purchases have been protected by the money-back guarantee.

Cellnovo, a company headquartered in London, provides a novel mobile system for managing type I diabetes. The Cellnovo system combines the benefits of a high-accuracy insulin patch pump, integrated activity monitor and a touchscreen, cellular enabled wireless handset with integrated blood glucose meter. The proprietary software is extremely easy to use and provides automatic connectivity to the cloud for real-time monitoring. The online data management system enables healthcare professionals to view clinical data in real time. This makes it a unique system enabling diabetics to lead a normal active life while keeping a close eye on their glycaemia, insulin use, activity and food intake.